Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
European indices posted gains today, supported by optimism from the U.S. stock market. The German DAX performed best, rising over 0.6%. The UK’s...
00:45The EUR/USD pair is surging nearly 0.6% today, while U.S. 10-year Treasury yields are down by 3.5 basis points, falling below the 4.26% level. Since...
00:35According to Bloomberg reports, Meta Platforms (META.US) plans to acquire PlayAI, an AI startup specializing in voice imitation. Although this segment...
ประเทศที่คุณเลือกไม่ได้รับการให้บริการ โปรดเลือกประเทศอื่น
การเปลี่ยนภาษามีผลกับการเปลี่ยนแปลงหน่วยงานควบคุม
